Who
Mace Rothenberg
Director
Company insider
Files Form 4 as: Director, Tango Therapeutics; Director, Surrozen.
In numbers
- Trades disclosed
- 19
- Buys
- 2
- Sells
- 0
- Bought
- $74K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 7 Jun 2022
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,550 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,550 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 14 May 2025filed 15 May 2025 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,333 at $0.00 | filing |
| 18 Nov 2024filed 18 Nov 2024 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Bought | $38K10,000 at $3.78 | filing |
| 14 Nov 2024filed 18 Nov 2024 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Bought | $36K10,000 at $3.62 | filing |
| 5 Jun 2024filed 7 Jun 2024 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 5 Jun 2024filed 6 Jun 2024 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,333 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 18 May 2023filed 19 May 2023 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 8 Jun 2022filed 28 Jun 2022 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | SRZN Surrozenoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In?TNGX · insidermonkey.com · 20 Oct 2026Tango Therapeutics (NASDAQ:TNGX) Shares Up 7.5% – Should You Buy?TNGX · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Mace Rothenberg; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.